Poor
Mostly Unaligned
Patient Risk:
Medium
Summary
Only one Lipitor-related concept (adjunct to diet/nonpharmacologic intervention in at-risk patients with hypercholesterolemia) is supported by the provided label excerpt. Most other Lipitor claims cannot be verified from the supplied label text (dosage, contraindications, warnings, interactions, studies, storage for forms beyond tablets). Multiple non–FDA-label claims about quercetin/supplements, NIH guidance, bleeding risk, and specific expert/article statements are unsupported because the provided FDA label excerpts contain no such information.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
Supported partially by label context in Section 1 (lipid-altering agents in hypercholesterolemia/atherosclerotic risk setting), but the provided excerpt does not explicitly state 'statin' or 'lower cholesterol levels' verbatim.
Lipitor is used to prevent cardiovascular disease.
Partially supported by Section 1 indicating therapy in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia and in patients with CHD or multiple risk factors for CHD (cardiovascular/atherosclerotic risk context), though the excerpt does not use the phrase 'prevent cardiovascular disease.'
Lipitor works by inhibiting the production of cholesterol in the liver.
Not supported by the provided label excerpts (Section 1 excerpt contains no mechanism).
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
Not supported by the provided label excerpts (Section 1 excerpt contains no LDL specifics).
Unsupported Statements
Lipitor works by inhibiting the production of cholesterol in the liver.
No mechanism of action is provided in the supplied label excerpts.
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
No LDL-lowering claim is provided in the supplied label excerpts.
Lipitor is available in tablet and oral solution forms.
The provided label information includes only oral tablets and Section 16 storage codes for tablets; no oral solution is supported by the excerpt.
Quercetin is an antioxidant flavonoid found in foods such as apples, onions, garlic, and leafy greens.
Not addressed in the provided Lipitor FDA label excerpts; quercetin content is outside the supplied label.
Quercetin is also available as a dietary supplement in capsule or powder form.
Not addressed in the provided FDA label excerpts.
Quercetin has anti-inflammatory properties.
Not addressed in the provided FDA label excerpts.
According to the National Institutes of Health (NIH), taking statins like Lipitor with certain supplements (including quercetin) may increase the risk of bleeding.
The supplied FDA label excerpts do not mention quercetin or NIH or bleeding-risk with quercetin; Section 7 excerpt addresses myopathy risk with specific drug classes only.
According to the National Institutes of Health (NIH), taking statins like Lipitor with certain supplements (including quercetin) may interact with other medications.
The supplied FDA label excerpts do not mention quercetin or NIH; Section 7 excerpt lists only certain concurrent drug classes as increasing myopathy risk.
Quercetin's anti-inflammatory properties may help alleviate symptoms of conditions like arthritis, allergies, and asthma.
Not addressed in the provided FDA label excerpts.
The patent for Lipitor (atorvastatin) expired in 2011, allowing generic versions to enter the market.
Patent/generic-market timing is not addressed in the supplied FDA label excerpts.
The patent for the extended-release formulation of Lipitor remains in effect until 2025.
Extended-release formulation patent timing is not addressed in the supplied FDA label excerpts.
Dr. Michael Greger advises that when taking Lipitor and quercetin, it is essential to monitor blood levels and adjust dosage accordingly.
No such guidance appears in the supplied FDA label excerpts (and quercetin is not addressed).
Dr. Michael Greger notes that the risk of bleeding from the interaction between quercetin and Lipitor is relatively low.
No such bleeding-risk discussion with quercetin appears in the supplied FDA label excerpts.
A study in the Journal of Medicinal Food found that quercetin supplementation reduced inflammation.
Clinical-study evidence about quercetin is not provided in the supplied FDA label excerpts.
A study in the Journal of Medicinal Food found that quercetin supplementation improved cardiovascular risk factors in patients with metabolic syndrome.
Clinical-study evidence about quercetin is not provided in the supplied FDA label excerpts.
Research suggests that Lipitor may affect the absorption of quercetin.
No quercetin absorption interaction is addressed in the supplied FDA label excerpts.
A study in the Journal of Agricultural and Food Chemistry found that atorvastatin reduced the bioavailability of quercetin in rats.
Animal-study results about quercetin are not provided in the supplied FDA label excerpts.
More human studies are needed to confirm whether Lipitor affects quercetin absorption.
Not addressed in the supplied FDA label excerpts.
Quercetin may offer additional benefits for individuals taking Lipitor, including reduced inflammation.
Not addressed in the supplied FDA label excerpts.
Quercetin's antioxidant effects may help protect against cardiovascular disease.
Not addressed in the supplied FDA label excerpts.
Quercetin has been shown to boost immune function and reduce the risk of infections.
Not addressed in the supplied FDA label excerpts.
The article states that Lipitor and quercetin can be taken together.
Not addressed in the supplied FDA label excerpts.
The article states that when taking Lipitor and quercetin together, it is essential to monitor blood levels and adjust dosages accordingly.
Not addressed in the supplied FDA label excerpts.
The article states that quercetin's anti-inflammatory effects may be beneficial for individuals taking Lipitor.
Not addressed in the supplied FDA label excerpts.
Quercetin may interact with other medications, including blood thinners, diabetes medications, and certain antibiotics.
Not addressed in the supplied FDA label excerpts.
Quercetin may affect blood sugar levels.
Not addressed in the supplied FDA label excerpts.
Contradictions
Low
AI Statement
Lipitor is available in tablet and oral solution forms.
Label Reference
Section 16 (How Supplied/Storage and Handling) excerpt provided only for tablets; no oral solution supported by provided label text.
Important Omissions
No FDA-label contraindications, boxed warnings, or specific warnings/precautions content is provided or evaluated for several key safety-related claims (e.g., bleeding risk, monitoring, dose adjustment) because the supplied label excerpts do not include those sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims reference supplement interactions (quercetin) and bleeding-risk/monitoring/dose adjustment that are not supported by the supplied FDA label excerpts. Mismatched interaction guidance can mislead clinical decision-making; additionally, dosage/contraindication/warning content was not provided for verification.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Most claims (especially about quercetin, NIH, bleeding risk, monitoring/dose adjustment, studies, and supplement compatibility) are not supported by the supplied FDA label excerpts. Lipitor mechanism and LDL-lowering specifics are also not supported by the provided label text.
Suggested Improvement
Restrict evaluation to claims directly supported by the provided label excerpts (e.g., Section 1 adjunct-to-diet/multiple risk factor intervention in hypercholesterolemia/atherosclerotic risk context; Section 7 myopathy-risk with specified drug classes). Remove or clearly mark as non-label statements any supplement-related/NIH/expert/article assertions that are not contained in the FDA label excerpts.